Sorry, you need to enable JavaScript to visit this website.

Skip to main content


JDRF partnership

Janssen Sets a Course to Intercept Type 1 Diabetes Together with JDRF

As part of its disease interception strategy to halt progression of type 1 diabetes (T1D) before the disease manifests, the Disease Interception Accelerator (DIA) began a research alignment with JDRF, a leading research and advocacy organization funding T1D research. The goal of the alignment is to inform and accelerate targeted and science-based solutions for T1D.

Disease Interception Accelerator

Disease Interception Accelerator